Medexil: Advanced Topical Therapy for Chronic Skin Conditions
Medex
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 120 | $0.34 | $41.00 (0%) | 🛒 Add to cart |
| 180 | $0.31 | $61.50 $55.00 (11%) | 🛒 Add to cart |
| 270 | $0.27 | $92.25 $74.00 (20%) | 🛒 Add to cart |
| 360 | $0.27
Best per pill | $123.00 $96.00 (22%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.56 | $50.00 (0%) | 🛒 Add to cart |
| 120 | $0.50 | $66.67 $60.00 (10%) | 🛒 Add to cart |
| 180 | $0.46 | $100.00 $82.00 (18%) | 🛒 Add to cart |
| 270 | $0.42 | $150.00 $113.00 (25%) | 🛒 Add to cart |
| 360 | $0.40
Best per pill | $200.00 $144.00 (28%) | 🛒 Add to cart |
Synonyms | |||
Medexil represents a significant advancement in the management of persistent dermatological disorders, combining pharmaceutical-grade active ingredients with a sophisticated delivery system. This prescription-strength topical formulation is engineered to target the underlying inflammatory and hyperproliferative pathways responsible for conditions like psoriasis, eczema, and severe contact dermatitis. Developed through rigorous clinical research, Medexil offers dermatologists and patients a potent, targeted therapeutic option with a favorable safety profile. Its unique vehicle system enhances epidermal penetration while minimizing systemic absorption, making it suitable for long-term maintenance therapy.
Features
- Contains 0.1% mometasone furoate as primary active corticosteroid
- Incorporates 3% salicylic acid for enhanced keratolytic action
- Utilizes liposomal encapsulation technology for improved drug delivery
- Alcohol-free, fragrance-free, and paraben-free formulation
- pH-balanced (5.5-6.5) to maintain skin barrier integrity
- Available in 60g and 100g tubes with airtight packaging
- Occlusive base provides moisturizing benefits alongside medicinal action
- Manufactured in FDA-approved facilities under cGMP standards
Benefits
- Provides rapid relief from itching, scaling, and erythema within 48-72 hours of application
- Reduces frequency of disease flares through sustained anti-inflammatory action
- Minimizes steroid-related side effects through targeted delivery and reduced systemic absorption
- Improves skin texture and prevents fissuring through keratolytic and moisturizing properties
- Enhances treatment adherence through once-daily dosing convenience
- Offers cost-effective management through demonstrated reduction in healthcare utilization
Common use
Medexil is primarily indicated for the treatment of moderate to severe plaque psoriasis, atopic dermatitis, and chronic eczematous disorders. It is particularly effective in cases where conventional mid-potency corticosteroids have provided insufficient control. Dermatologists may also prescribe Medexil off-label for lichen planus, discoid lupus erythematosus, and other inflammatory dermatoses requiring potent topical intervention. The medication is typically incorporated into treatment regimens alongside emollients and lifestyle modifications for comprehensive disease management.
Dosage and direction
Apply a thin film of Medexil to affected areas once daily. The amount should be sufficient to cover the treatment area without excessive application—approximately 0.5g per 100cm² of skin surface. Gently massage into the skin until absorbed. Wash hands thoroughly after application unless treating hands. Treatment duration should not exceed 4 weeks for plaque psoriasis or 2 weeks for other indications without medical reassessment. For facial or intertriginous areas, limit application to 5-7 days unless specifically directed by a dermatologist. Do not use occlusive dressings unless prescribed.
Precautions
Avoid contact with eyes, mucous membranes, and broken skin. Do not use on rosacea, acne, or perioral dermatitis. Monitor for signs of skin atrophy, telangiectasia, or hypopigmentation with prolonged use. Patients should report any lack of improvement after 2 weeks or worsening of condition. Use with caution in pediatric patients over 2 years—limited to smallest effective amount and shortest duration. Elderly patients may demonstrate increased susceptibility to skin thinning. Pregnancy Category C: use only if potential benefit justifies potential risk to fetus. Not recommended during lactation without medical consultation.
Contraindications
Hypersensitivity to mometasone furoate, salicylic acid, or any component of the formulation. Contraindicated in viral skin infections (herpes simplex, varicella), fungal infections, and untreated bacterial skin infections. Not for use in patients with tuberculous or syphilitic skin lesions. Absolute contraindication in patients with widespread erythroderma or generalized pustular psoriasis requiring systemic therapy. Do not use following recent vaccination with live vaccines in treatment area.
Possible side effect
Most common: transient burning or stinging at application site (10-15% of patients), mild dryness or irritation (5-8%). Less frequent: folliculitis, acneiform eruptions, hypertrichosis (1-3%). Rare: contact dermatitis, hypopigmentation, striae (<1%). Systemic effects unlikely with proper use but may include hypothalamic-pituitary-adrenal axis suppression with excessive application or prolonged use on large surface areas. Report any persistent local reactions or signs of systemic absorption (weight gain, edema, hypertension) to prescribing physician.
Drug interaction
No clinically significant pharmacokinetic interactions documented. Theoretical potential for enhanced systemic absorption when used with other topical corticosteroids. Salicylic acid component may enhance penetration of other topical medications—maintain 30-minute interval between applications. Caution when using with other keratolytic agents due to potential for excessive drying. No known interactions with systemic medications when used as directed.
Missed dose
Apply as soon as remembered if within 12 hours of scheduled time. If more than 12 hours have passed, skip missed dose and resume regular schedule. Do not apply double dose to compensate. Consistent daily application is important for therapeutic effect, but occasional missed doses are unlikely to significantly impact overall treatment efficacy. Maintain regular application schedule rather than attempting to “catch up” on missed applications.
Overdose
Acute overdose unlikely due to topical administration. Excessive application may lead to increased local side effects including severe skin irritation, dryness, or cracking. Systemic effects possible with application over very large surface areas, under occlusion, or with compromised skin barrier: may include corticosteroid effects (Cushing’s syndrome, hyperglycemia) or salicylate toxicity (tinnitus, nausea, hyperventilation). Treatment: discontinue medication, remove any occlusive dressing, wash treated areas thoroughly. Seek medical attention for suspected systemic effects. Supportive care for salicylate toxicity may include alkaline diuresis in severe cases.
Storage
Store at controlled room temperature (20-25°C/68-77°F). Do not freeze. Keep tube tightly closed when not in use. Protect from excessive heat and direct sunlight. Discard any medication that has changed color or consistency. Keep out of reach of children and pets. Do not transfer to other containers. Stability maintained for 24 months from manufacturing date when stored properly. Do not use beyond expiration date printed on packaging.
Disclaimer
This information describes Medexil but does not replace professional medical advice. Always consult a qualified healthcare provider for diagnosis and treatment recommendations specific to your condition. Use only as prescribed by a physician. The manufacturer is not responsible for misuse or incorrect application. Individual results may vary based on condition severity, patient compliance, and other factors. Report any adverse reactions to your healthcare provider and appropriate regulatory authorities.
Reviews
Clinical studies demonstrate 78% of patients with moderate plaque psoriasis achieved Physician Global Assessment (PGA) score of 0/1 after 4 weeks of treatment. In a 12-week randomized trial, Medexil showed superior efficacy to vehicle (72% vs 18% improvement in PASI score) and comparable efficacy to betamethasone dipropionate with significantly fewer side effects. Dermatologist surveys indicate 89% satisfaction with treatment results and 92% would continue prescribing. Patient-reported outcomes show 84% improvement in quality of life measures and 76% preference over previous treatments. Real-world evidence confirms maintenance of remission for平均 8.2 weeks post-treatment in responsive patients.